Literature DB >> 11223966

Large-scale mobilization and isolation of CD34+ cells from normal donors.

J M Croop1, R Cooper, R Seshadri, C Fernandez, V Graves, S Kreissman, F O Smith, K Cornetta, D A Williams, R Abonour.   

Abstract

We describe collection and purification of peripheral blood CD34+ cells from volunteer, normal donors and allogeneic stem cell donors. A total of 98 aphereses were performed on 68 volunteer donors using peripheral venous access. The mean number of nucleated cells collected was 4.6 x 10(10) which included 1.9 x 10(8) CD34+ cells corresponding to 2.7 x 10(6) CD34+ cells/kg. The number of CD34+ cells collected did not differ between males and females but did correlate with the donor's weight and the total number of nucleated cells collected. The Nexell Isolex 300i cell separator was used to isolate CD34+ cells from 30 of the collections. A mean of 0.36% of the total cells was recovered and included 43 +/- 18% of the CD34+ cells. CD34+ cells represented 85 +/- 11% of the recovered cells. The total number of CD34+ cells recovered was not influenced by the number of nucleated cells placed on the Isolex 300i. The percentage of CD34+ cells recovered was not related to the number of CD34+ cells placed on the Isolex 300i. The purity of the final product was influenced by the number of CD34+ cells but not the total number of nucleated cells. An additional 38 CD34+ cell isolations were performed on normal allogeneic stem cell donors with similar results. These observations further support the safety and feasibility of peripheral blood CD34+ cell collection and purification.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11223966     DOI: 10.1038/sj.bmt.1702720

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  1 in total

1.  CD46 Null Packaging Cell Line Improves Measles Lentiviral Vector Production and Gene Delivery to Hematopoietic Stem and Progenitor Cells.

Authors:  Stosh Ozog; Craig X Chen; Elizabeth Simpson; Olivia Garijo; Nina D Timberlake; Petra Minder; Els Verhoeyen; Bruce E Torbett
Journal:  Mol Ther Methods Clin Dev       Date:  2018-11-24       Impact factor: 6.698

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.